• Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Njideka Ulunma Okubadejo, Katja Lohmann, Huw R Morris, Tzi Shin Toh, Yi Wen Tay, Lara M Lange, Sara Bandres-Ciga, Ignacio Mata, Jia Nee Foo, Esther Sammler, Joshua Chin Ern Ooi, Alastair J Noyce, Natascha Bahr, Wei Luo, Rajeev Ojha, Andrew B Singleton, Cornelis Blauwendraat, and Christine Klein.
• Division of Neurology, Department of Medicine, and The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: sylim@ummc.edu.my.
• Lancet Neurol. 2024 Dec 1; 23 (12): 126712801267-1280.

AbstractKnowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, caused by a mutation in α-synuclein, and with the subsequent identification of multiple other causative genes and associated loci. Genetic studies provide insights into the phenotypic heterogeneity and global distribution of Parkinson's disease. By shedding light on the underlying biological mechanisms, genetics facilitates the identification of new biomarkers and therapeutic targets. Several clinical trials of genetics-informed therapies are ongoing or imminent. International programmes in populations who have been under-represented in Parkinson's disease genetics research are fostering collaboration and capacity-building, and have already generated novel findings. Many challenges remain for genetics research in these populations, but addressing them provides opportunities to obtain a more complete and equitable understanding of Parkinson's disease globally. These advances facilitate the integration of genetics into the clinic, to improve patient management and personalised medicine.Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

21 keywords...

hide…